On April 8 th, the company announced that they have entered into a definitive merger agreement with Ocugen. The proposed merger will result in a combined publicly-traded, clinical-stage The merger is structured as a stock-for-stock transaction whereby all of Ocugen’s outstanding shares of common stock and securities convertible into or exercisable for Ocugen’s common stock will be converted into Histogenics’ common stock and securities convertible into or exercisable for Histogenics’ common stock. HSGX is about to undergo a reverse-merger. HSGX is being bought out by Ocugen as a shell for Ocugen's makeshift "IPO," which per HSGX investor relations will happen by the end of next week when they're expected to file the S-4. Ocugen has a novel drug therapy for Ocular GVHD (OCU-300/310,) and is a phase 3 drug awaiting results and FDA approval.

HSGX: Get the latest Histogenics stock price and detailed information including Histogenics Corporation Announces Approval of Merger by Stockholders at  Stock Price Forecast for HSGX: Histogenics Corporation holds several negative signals and is within a very wide and falling trend, so we believe it will still  Lookup the fund or stock ticker symbol for any company on any exchange in any country at Marketwatch. 30 Sep 2019 Ocugen Announces Completion of its Merger with Histogenics to Create merger with Histogenics Corporation (previously NASDAQ: HSGX), and the trading today on The Nasdaq Capital Market under the ticker symbol “OCGN. As a result of the merger, after taking into account the reverse stock split, 

BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with

Histogenics Corporation (NASDAQ: HSGX) and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming to develop novel ocular gene therapies and Get the latest %COMPANY_NAME% HSGX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. - HSGX - Stock Price Today - Zacks HSGX is 0.18% today, BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with HSGX has risen $0.12 from the previous closing price of $0.11 on volume of 32,612,040 shares. Over the past year the S&P 500 is up 10.40% while HSGX has fallen -91.58%. HSGX lost -$0.23 per share the over the last 12 months. On April 8 th, the company announced that they have entered into a definitive merger agreement with Ocugen. The proposed merger will result in a combined publicly-traded, clinical-stage The merger is structured as a stock-for-stock transaction whereby all of Ocugen’s outstanding shares of common stock and securities convertible into or exercisable for Ocugen’s common stock will be converted into Histogenics’ common stock and securities convertible into or exercisable for Histogenics’ common stock.

Company Name: Ocugen Inc, Stock Symbol: OCGN, Industry: Biotechs, Total Posts: 1403, Last Post: 3/3/2020 8:56:04 AM.

Get the latest %COMPANY_NAME% HSGX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. - HSGX - Stock Price Today - Zacks HSGX is 0.18% today,

3 Sep 2019 Though the stock is nowhere near it's price last year, HSGX stock has sentence from the company's original merger announcement in April.

HSGX is about to undergo a reverse-merger. HSGX is being bought out by Ocugen as a shell for Ocugen's makeshift "IPO," which per HSGX investor relations will happen by the end of next week when they're expected to file the S-4. Ocugen has a novel drug therapy for Ocular GVHD (OCU-300/310,) and is a phase 3 drug awaiting results and FDA approval.

One share of HSGX stock can currently be purchased for approximately $0.31. How big of a company is Histogenics? Histogenics has a market capitalization of $28.98 million.

Foamix Pharmaceuticals (FOMX) performed a stock merger. Shareholders will receive $22.09 cash per each share of SYMBOL previously held. shareholders will now hold 1 share of OCGN for every 60 shares of HSGX previously held. HSGX: Get the latest Histogenics stock price and detailed information including HSGX news, historical charts and realtime prices. Histogenics and Ocugen Enter into Definitive Merger Agreement Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. One share of HSGX stock can currently be purchased for approximately $0.31. How big of a company is Histogenics? Histogenics has a market capitalization of $28.98 million. Histogenics Corporation (NASDAQ: HSGX) and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming to develop novel ocular gene therapies and

30 Sep 2019 Ocugen Announces Completion of its Merger with Histogenics to Create merger with Histogenics Corporation (previously NASDAQ: HSGX), and the trading today on The Nasdaq Capital Market under the ticker symbol “OCGN. As a result of the merger, after taking into account the reverse stock split,  Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 1.25, with a high estimate of 1.25 and a low  Stock analysis for Ocugen Inc (HSGX) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Ocugen, Inc. Common Stock (OCGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 26 Sep 2019 Histogenics Corporation (HSGX) (the “Company” or “Histogenics”) to “Ocugen, Inc.” and the Nasdaq trading symbol will become “OCGN. 3 Sep 2019 Though the stock is nowhere near it's price last year, HSGX stock has sentence from the company's original merger announcement in April.